Core Insights - Molina Healthcare Inc. shares experienced a significant decline of 19.34% to $157.39 in after-hours trading following the release of its third-quarter earnings [1] Financial Performance - The company reported third-quarter GAAP earnings of $1.51 per diluted share, a decrease from $5.65 in the same quarter last year [2] - Adjusted earnings were $1.84 per share, down from $6.01 year-over-year [2] - Premium revenue increased by 12% year-over-year, reaching $10.8 billion [2] Medical Care Ratios - The consolidated medical care ratio (MCR) for Q3 rose to 92.6%, up from 89.2% a year earlier [3] - Medicaid MCR was reported at 92.0%, Medicare at 93.6%, and Marketplace at 95.6% [3] Earnings Contribution - Medicaid contributed $3.52 per diluted share to adjusted earnings, while losses from Medicare and Marketplace amounted to $1.68 per share [4] Full-Year Guidance - The company revised its premium revenue forecast to approximately $42.5 billion and expects full-year 2025 adjusted earnings of around $14 per diluted share [5] - The outlook change is attributed to rising medical costs across all segments, with the Marketplace business facing "unprecedented" cost trends [5] Preliminary Outlook for 2026 - The preliminary outlook for adjusted earnings per share in 2026 is expected to be similar to the full-year 2025 guidance, with reduced exposure to the Marketplace [6] Stock Performance - Molina Healthcare's stock has declined 32.96% year-to-date in 2025, trading within a range of $151.95 to $359.97 [7] - The company has a market capitalization of $10.58 billion, an average daily volume of 1.04 million shares, and a price-to-earnings ratio of 9.62 [7]

The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose: (1) material, adverse facts concerning Molina's "medical cost trend assumptions"; (2) that Molina was experiencing a "dislocation between premium rates and medical cost trend"; (3) that Molina's near term growth was dependent on a lack of "utilization of behavioral health, pharmacy, and inpatient and outpatient services"; (4) as a result, Molina's financial guidance for fisc ...

Core Insights - Molina (MOH) reported $11.48 billion in revenue for Q3 2025, marking an 11% year-over-year increase, but EPS fell to $1.84 from $6.01 a year ago, indicating a significant decline in profitability [1] - The revenue exceeded the Zacks Consensus Estimate of $10.9 billion by 5.28%, while the EPS fell short of the consensus estimate of $3.97 by 53.65% [1] Financial Performance Metrics - Molina's total Membership Care Ratio (MCR) was 92.6%, surpassing the average estimate of 90.3% [4] - The MCR for Medicare was reported at 93.6%, exceeding the estimated 87% [4] - The MCR for Marketplace was 95.6%, compared to the estimated 84.7% [4] Membership and Revenue Breakdown - Total ending membership was 5.63 million, slightly below the average estimate of 5.74 million [4] - Medicaid membership stood at 4.64 million, compared to the estimated 4.8 million [4] - Premium revenue reached $10.84 billion, exceeding the estimate of $10.31 billion, reflecting an 11.8% increase year-over-year [4] - Premium tax revenue was $506 million, slightly above the estimate of $474.87 million, but showed a year-over-year decline of 0.4% [4] - Medicare premium revenue was $1.61 billion, surpassing the estimate of $1.48 billion, with a year-over-year increase of 17.8% [4] - Medicaid premium revenue was $8.02 billion, exceeding the estimate of $7.66 billion, reflecting a 4.5% year-over-year increase [4] - Marketplace premium revenue was $1.2 billion, significantly above the estimate of $1.1 billion, showing an impressive 81.6% increase year-over-year [4] - Investment income was reported at $108 million, exceeding the estimate of $99.93 million, but reflecting an 8.5% year-over-year decline [4] - Other revenue was $22 million, slightly above the estimate of $21.47 million, with a year-over-year increase of 10% [4] Stock Performance - Molina's shares have returned +7.8% over the past month, outperforming the Zacks S&P 500 composite's +1.1% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Molina's quarterly earnings were reported at $1.84 per share, significantly missing the Zacks Consensus Estimate of $3.97 per share, representing an earnings surprise of -53.65% [1] - The company posted revenues of $11.48 billion for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 5.28% and showing an increase from $10.34 billion year-over-year [2] - Molina's stock has underperformed, losing approximately 32.4% since the beginning of the year, while the S&P 500 has gained 14.5% [3] Earnings Performance - Over the last four quarters, Molina has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is $3.38, with expected revenues of $11.07 billion, and for the current fiscal year, the EPS estimate is $18.87 on revenues of $44.54 billion [7] Market Outlook - The company's earnings outlook is crucial for investors, as it reflects current consensus expectations and any recent changes [4] - The trend of estimate revisions for Molina was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] - The Medical - HMOs industry, to which Molina belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a favorable industry outlook [8] Competitor Insights - Cigna, another company in the same industry, is expected to report quarterly earnings of $7.70 per share, reflecting a year-over-year increase of 2.5%, with revenues projected at $67.19 billion, up 5.5% from the previous year [9]

Core Points - A class action lawsuit has been filed against Molina Healthcare, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial guidance during the Class Period from February 5, 2025, to July 23, 2025 [3][7] - The lawsuit claims that Molina failed to disclose adverse facts about its medical cost trend assumptions and the dislocation between premium rates and medical costs, which could lead to a significant cut in financial guidance for fiscal year 2025 [3][7] Allegation Details - Defendants allegedly made false statements about the company's medical cost trend assumptions [3] - Molina was said to be experiencing a dislocation between premium rates and medical costs [3] - The company's near-term growth was reportedly dependent on a lack of utilization of various health services [3] - As a result of these issues, Molina's financial guidance for fiscal year 2025 was likely to be cut [3] - Positive statements made by the defendants about the company's prospects were claimed to be materially misleading [3] Next Steps - Investors who purchased Molina shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][7] - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is December 2, 2025 [7]

Molina Healthcare on Wednesday cut its annual profit forecast anticipating higher medical care costs to weigh on its results for the rest of the year. ...

News Release Investor Contact: Jeffrey Geyer, Jeffrey.Geyer@molinahealthcare.com, 305-317-3012 Media Contact: Caroline Zubieta, Caroline.Zubieta@molinahealthcare.com, 562-951-1588 Molina Healthcare Reports Third Quarter 2025 Financial Results Revises Full Year 2025 Guidance | | Three months ended | | Nine months ended | | | --- | --- | --- | --- | --- | | | September 30, | | September 30, | | | | 2025 | 2024 | 2025 | 2024 | | (In millions, except per-share results) | | | | | | Premium Revenue | $10,841 | $9 ...

NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Molina Healthcare, Inc. (NYSE: MOH) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Molina, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/molina-healthcare-inc-class-action. Investors have until December 2, 2025, to ask the Court to be appoin ...

Core Viewpoint - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with specific deadlines for filing lead plaintiff motions [1] Group 1: Fortinet, Inc. (NASDAQ: FTNT) - Class period is from November 8, 2024, to August 6, 2025, with a lead plaintiff deadline of November 21, 2025 [2] - Allegations include false and misleading statements regarding the refresh cycle's profitability, lack of clarity on upgradeable FortiGate firewalls, and misrepresentation of the refresh momentum [2] Group 2: Molina Healthcare, Inc. (NYSE: MOH) - Class period is from February 5, 2025, to July 23, 2025, with a lead plaintiff deadline of December 2, 2025 [3] - Allegations include failure to disclose adverse facts about medical cost trend assumptions, dependency on low utilization of services for growth, and likely cuts to financial guidance for fiscal year 2025 [3] Group 3: Marex Group plc (NASDAQ: MRX) - Class period is from May 16, 2024, to August 5, 2025, with a lead plaintiff deadline of December 8, 2025 [4] - Allegations include selling over-the-counter financial instruments to itself, inconsistencies in financial statements, and unreliability of Marex's financial disclosures [4]

Core Insights - Molina (MOH) is expected to report quarterly earnings of $3.97 per share, reflecting a decline of 33.9% year-over-year, while revenues are forecasted to reach $10.9 billion, an increase of 5.4% year-over-year [1] - The consensus EPS estimate has been revised upward by 7.8% in the past 30 days, indicating a reassessment of initial estimates by analysts [1][2] Revenue Projections - Analysts predict 'Revenue- Premium revenue' at $10.31 billion, a change of +6.3% from the prior-year quarter [4] - 'Revenue- Premium tax revenue' is estimated to be $474.87 million, indicating a decline of -6.5% year-over-year [4] - 'Revenue- Premium revenue- Medicare' is projected to reach $1.48 billion, reflecting an increase of +8% from the prior-year quarter [4] - The consensus estimate for 'Revenue- Premium revenue- Medicaid' stands at $7.66 billion, suggesting a slight decline of -0.1% year-over-year [5] Membership and MCR Estimates - 'Ending Membership by Program - Total' is expected to be 5.74 million, up from 5.60 million year-over-year [6] - 'MCR - Total' is projected at 90.3%, an increase from 89.2% in the previous year [5] - 'MCR - Medicare' is expected to be 87.0%, down from 89.6% in the same quarter last year [5] - 'MCR - Marketplace' is forecasted at 84.7%, up from 73.0% year-over-year [6] - 'Ending Membership by Program - Medicaid' is estimated to reach 4.80 million, down from 4.94 million year-over-year [6] - 'Ending Membership by Program - Medicare' is projected at 263.02 thousand, an increase from 247.00 thousand year-over-year [7] - 'Ending Membership by Program - Marketplaces' is expected to be 659.47 thousand, up from 410.00 thousand year-over-year [7] Market Performance - Molina shares have returned +8.6% over the past month, outperforming the Zacks S&P 500 composite's +1.2% change [8] - Despite recent performance, Molina holds a Zacks Rank 5 (Strong Sell), indicating expectations of underperformance relative to the overall market in the near future [8]